|

Lurbinectedin Clinical Trials

17 actively recruiting trials across 12 locations

▲ +2 trials since July 2026

Also known as: JZP712, PM01183, Zepzelca

Pipeline

Phase 1: 2Phase 2: 7Phase 3: 3Phase 1/2: 5

Top Sponsors

  • Jazz Pharmaceuticals2
  • AbbVie2
  • VA Office of Research and Development1
  • UNC Lineberger Comprehensive Cancer Center1
  • Phanes Therapeutics1

Indications

  • Cancer17
  • Lung Cancer13
  • Small Cell Lung Cancer5
  • Desmoplastic Small Round Cell Tumor2
  • Relapsed Small Cell Lung Cancer2

Other3 trials

Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
Phase 2
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Phase 2

Los Angeles, California3 trials

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Valkyrie Clinical Trials, Inc.

Phase 2
Lurbinectedin in FET-Fused Tumors

Cedars-Sinai Medical Center

Phase 1/2
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Children's Hospital of Los Angeles

Phase 1/2

Birmingham, Alabama1 trial

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063

Phase 3

Springdale, Arkansas1 trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Highlands Oncology Group

Phase 3

Duarte, California1 trial

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Palo Alto, California1 trial

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

VA Palo Alto Health Care System, Palo Alto, CA

Phase 1/2

New Haven, Connecticut1 trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Yale University School of Medicine /ID# 278181

Phase 2

Atlanta, Georgia1 trial

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Emory University Hospital Midtown

Phase 1

Indianapolis, Indiana1 trial

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 1/2

Bethesda, Maryland1 trial

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center

Phase 2

Lebanon, New Hampshire1 trial

Study of Trilaciclib and Lurbinectidin

Dartmouth Hitchcock Medical Center

Phase 2

Philadelphia, Pennsylvania1 trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Houston, Texas1 trial

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.